According to a recent LinkedIn post from Resolution Therapeutics, the company plans to attend the American Society of Gene & Cell Therapy 29th Annual Meeting in Boston in May 2026. The post indicates that Senior Vice President and Head of Research and Translational Science, Lara Campana, is scheduled to present preclinical data on the firm’s regenerative macrophage therapy RTX001.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post notes that RTX001 is being developed as a regenerative macrophage therapy for end-stage liver disease and is currently under evaluation in the Phase I/II EMERALD clinical trial. The presentation, described as part of a session on novel T cell and myeloid strategies, could help raise the profile of Resolution Therapeutics’ platform among scientific peers and potential partners.
From an investor perspective, the planned disclosure of preclinical data at a major gene and cell therapy conference suggests ongoing progress in the company’s lead program. Visibility at ASGCT may support Resolution Therapeutics’ positioning within the cell and gene therapy ecosystem and could influence future partnering, funding discussions, or perceptions of the clinical and commercial potential of RTX001.